LL-37 is a human cathelicidin peptide with powerful antimicrobial, immune-modulating, and pro-healing properties. Not only does it kill pathogens directly, but it also boosts immune responses and supports tissue repair - making it a promising option for persistent infections or slow-healing wounds.

1. Antimicrobial & Anti-Biofilm Effects:
   • Destroys microbial membranes of bacteria, fungi, and viruses through pore formation or carpet-like disruption.
   • Effective against drug-resistant strains like MRSA and Pseudomonas.
   • Breaks down biofilms that make infections difficult to eliminate.
2. Wound Healing & Angiogenesis:
   • Promotes new blood vessel growth (angiogenesis) and skin regeneration.
   • A 2023 randomized controlled trial (RCT) showed LL-37 significantly improved granulation tissue in diabetic foot ulcers.
   • Topical LL-37 in hydrogels enhanced healing and reduced inflammation in chronic wounds.
3. Immunomodulatory Pathways:
   • LL-37 neutralizes bacterial endotoxins (like LPS) and modulates toll-like receptor (TLR) signaling.
   • It activates antiviral responses while preventing overactive inflammatory processes like pyroptosis.
   • Helps balance pro- and anti-inflammatory immune signals.
4. Safety & Dosage:
   • Topical LL-37 has been well tolerated in clinical studies.
   • Injectable use is considered investigational.
   • Doses often start at 100-200 mcg, subcutaneously, 2-3x/week, with cycles of 4-8 weeks.
   • Herxheimer reactions (immune flare-ups) may occur and indicate detox or microbial die-off.

---

Why It Matters for Patients

With rising antibiotic resistance and persistent immune dysregulation, LL-37 offers a multi-functional, natural mechanism of support for healing, immune balancing, and infection control. While still investigational, it's a promising peptide for those seeking comprehensive integrative care.

---

Take the Next Step

Interested in whether LL-37 peptide therapy is right for your healing journey? Schedule a consultation at Lake Norman Integrative Wellness today. Visit www.drakibagreen.com or call us directly to learn more.

---

Key References

1. Miranda et al., 2023 - Randomized trial showing improved healing of diabetic foot ulcers with LL-37.
2. Zanetti M. et al., Frontiers in Immunology - Reviews antimicrobial and immune-regulatory roles of cathelicidins.
3. Coorens M. et al., IJMS 2020 - Overview of LL-37's therapeutic potential.
4. Nagaoka et al., 2021 - Biofilm disruption and immune balancing activity.

Disclaimer: LL-37 is not FDA-approved for therapeutic use. It is used in research and under physician guidance only. This document is educational and does not replace medical advice.